We are developing a cutting-edge liquid biopsy platform for the early diagnosis and monitoring of brain tumors, particularly glioblastoma and metastatic brain cancers with pan-tumor potential. Our proprietary biomarkers are the first non-invasive liquid biopsy solution enabling tumor-specific extracellular vesicle (EV) detection that can reliably detect early stage tumors. Scalability is enabled by our novel hardware for automated high-throughput quantification, isolation and downstream EV analysis. As a multi-disciplinary team (USZ & ETH), we provide an affordable and highly scalable diagnostic solution. The global market size for early tumor detection and disease monitoring is ~ 45bn CHF.